278 related articles for article (PubMed ID: 12851603)
1. Vasopressin: a new target for the treatment of heart failure.
Lee CR; Watkins ML; Patterson JH; Gattis W; O'connor CM; Gheorghiade M; Adams KF
Am Heart J; 2003 Jul; 146(1):9-18. PubMed ID: 12851603
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin antagonism: a future treatment option in heart failure.
Sanghi P; Uretsky BF; Schwarz ER
Eur Heart J; 2005 Mar; 26(6):538-43. PubMed ID: 15695526
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin and vasopressin receptor antagonists in heart failure.
Oghlakian G; Klapholz M
Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
[TBL] [Abstract][Full Text] [Related]
4. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
[TBL] [Abstract][Full Text] [Related]
5. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
6. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
Schwarz ER; Sanghi P
Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
[TBL] [Abstract][Full Text] [Related]
7. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
Goldsmith SR
Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
[TBL] [Abstract][Full Text] [Related]
8. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
[TBL] [Abstract][Full Text] [Related]
9. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
[TBL] [Abstract][Full Text] [Related]
10. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
11. Neurohormonal activation in congestive heart failure and the role of vasopressin.
Chatterjee K
Am J Cardiol; 2005 May; 95(9A):8B-13B. PubMed ID: 15847852
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.
Wada K; Fujimori A; Matsukawa U; Arai Y; Sudoh K; Yatsu T; Sasamata M; Miyata K
Eur J Pharmacol; 2005 Jan; 507(1-3):145-51. PubMed ID: 15659304
[TBL] [Abstract][Full Text] [Related]
15. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
Rai A; Whaley-Connell A; McFarlane S; Sowers JR
Am J Nephrol; 2006; 26(6):579-89. PubMed ID: 17170524
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
Reilly T; Schork MR
Ann Pharmacother; 2010 Apr; 44(4):680-7. PubMed ID: 20332337
[TBL] [Abstract][Full Text] [Related]
18. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Ferguson JW; Therapondos G; Newby DE; Hayes PC
Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
[TBL] [Abstract][Full Text] [Related]
20. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
